Alcon（1ALC）株式概要アルコン社は、アイケア製品の研究、開発、製造、流通、販売を世界中で行っている。 詳細1ALC ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長3/6過去の実績2/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より35.8%で取引されている 収益は年間18.14%増加すると予測されています アナリストらは、株価が43.8%上昇するだろうとほぼ一致している。 リスク分析利益率(7.7%)は昨年より低い(11.3%) すべてのリスクチェックを見る1ALC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€57.581.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-604m14b2016201920222025202620282031Revenue US$14.3bEarnings US$1.1bAdvancedSet Fair ValueView all narrativesAlcon Inc. 競合他社DiaSorinSymbol: BIT:DIAMarket cap: €3.5bMedlineSymbol: NasdaqGS:MDLNMarket cap: US$47.2bSvas BiosanaSymbol: BIT:SVSMarket cap: €48.4mHOYASymbol: TSE:7741Market cap: JP¥9.0t価格と性能株価の高値、安値、推移の概要Alcon過去の株価現在の株価CHF 57.5852週高値CHF 79.0052週安値CHF 52.42ベータ0.701ヶ月の変化-1.37%3ヶ月変化-13.41%1年変化-21.66%3年間の変化n/a5年間の変化n/aIPOからの変化15.16%最新ニュースValuation Update With 7 Day Price Move • May 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €53.20, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Medical Equipment industry in Italy. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €84.18 per share.お知らせ • May 08+ 1 more updateAlcon Inc. (SWX:ALC) announces an Equity Buyback for $1,500 million worth of its shares.Alcon Inc. (SWX:ALC) announces a share repurchase program. Under the program, the company will repurchase up to $1,500 million worth of its shares. The shares to be acquired under this share buyback program will be cancelled as a return of capital to shareholders. The repurchases will be funded through cash generated from operations. The repurchase program will be valid for 3 years.New Risk • May 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.7% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.お知らせ • May 02Alcon Inc. Elects R. Scott Herren as New Independent Member of the BoardAlcon Inc. at its Annual General Meeting of 2026 elected R. Scott Herren as new independent member of the Board.Upcoming Dividend • Apr 28Upcoming dividend of CHF0.28 per shareEligible shareholders must have bought the stock before 05 May 2026. Payment date: 07 May 2026. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.6%). Lower than average of industry peers (2.3%).Board Change • Apr 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • May 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €53.20, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Medical Equipment industry in Italy. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €84.18 per share.お知らせ • May 08+ 1 more updateAlcon Inc. (SWX:ALC) announces an Equity Buyback for $1,500 million worth of its shares.Alcon Inc. (SWX:ALC) announces a share repurchase program. Under the program, the company will repurchase up to $1,500 million worth of its shares. The shares to be acquired under this share buyback program will be cancelled as a return of capital to shareholders. The repurchases will be funded through cash generated from operations. The repurchase program will be valid for 3 years.New Risk • May 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.7% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.お知らせ • May 02Alcon Inc. Elects R. Scott Herren as New Independent Member of the BoardAlcon Inc. at its Annual General Meeting of 2026 elected R. Scott Herren as new independent member of the Board.Upcoming Dividend • Apr 28Upcoming dividend of CHF0.28 per shareEligible shareholders must have bought the stock before 05 May 2026. Payment date: 07 May 2026. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.6%). Lower than average of industry peers (2.3%).Board Change • Apr 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 07Alcon Inc Launches Clareon Truplus Enhanced Design Monofocal And Toric IOLsAlcon Inc. announced the U.S. launch of Clareon TruPlus, its new enhanced design monofocal and toric intraocular lens (IOL), at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. TruPlus expands Alcon’s Clareon portfolio, offering surgeons an enhanced design IOL, enabling increased depth of focus without compromising the high-quality distance vision they expect from a monofocal IOL. Based on bench data, TruPlus has a number of differentiating features over Clareon Monofocal and the leading competitor IOL. TruPlus demonstrates a 3.5 letter improvement in simulated visual acuity at -1.5 diopters (66 cm) compared to Clareon Monofocal. TruPlus offers higher distance image quality than TECNIS Eyhance across a range of pupil sizes and lighting conditions. TruPlus exceeds the ISO upper requirement for distance image quality. TruPlus demonstrates a lower glare and halo profile than TECNIS Eyhance. TruPlus leverages proprietary Opti-Balance Technology in the center of the lens to slightly extend the depth of focus. This innovative design boosts light energy for an increased depth of focus, while maintaining exceptional distance image quality and a wide refractive landing zone. With more than 175 million IOLs implanted globally, TruPlus joins Alcon’s portfolio of Clareon IOLs that includes the number one monofocal; Vivity, the extended depth of focus IOL; PanOptix Pro and PanOptix, the trifocal IOL. TruPlus will launch in additional markets later this year. At ASCRS, Alcon will also feature more than 60 scientific presentations and peer-to-peer educational symposia. Studies presented include First Clinical Experience with a Novel Phacoemulsification System, Anterior Chamber Stability of a Novel Phacoemulsification System Assessed by Intraoperative OCT and Surgical Microscope Video, Prospective Intraindividual Comparison of Functional Outcomes After Automated Customized Ray Tracing Guided vs. Wavefront Optimized LASIK, Perioperative Benefits of a Personalized LASIK Approach Using 3D Ray Tracing Technology: A Modified Delphi Study, High Tear Production Responder Rates Associated with the Novel TRPM8 Agonist Acoltremon: Phase 3 COMET2 and COMET3 Results, Tear Volume and Total Lipid Concentration Following Administration of Acoltremon 0.003%, Optical Bench Comparison of Two Enhanced Monofocal IOLs, and Direct Comparison of the Visual Disturbances Induced by Two Enhanced Monofocal IOLs. The Clareon Family of Lenses are artificial lenses implanted in the eye of adult patients following cataract surgery. The Clareon TruPlus IOLs are designed to allow for clear distance vision. The Clareon TruPlus Toric IOLs are designed to correct pre-existing corneal astigmatism, which is the inability of the eye to focus clearly at any distance because of different curvatures on the cornea, and provide distance vision. These IOLs are intended for placement in the capsular bag. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon, informing them of possible risks and benefits associated with these IOLs. Reference the Directions for Use labelling for each IOL for a complete listing of indications, warnings and precautions.Declared Dividend • Apr 05Dividend of CHF0.28 announcedShareholders will receive a dividend of CHF0.28. Ex-date: 5th May 2026 Payment date: 7th May 2026 Dividend yield will be 0.4%, which is lower than the industry average of 1.7%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 11%.お知らせ • Apr 03Alcon Inc. announces Annual dividend, payable on May 07, 2026Alcon Inc. announced Annual dividend of CHF 0.2800 per share payable on May 07, 2026, ex-date on May 05, 2026 and record date on May 06, 2026.お知らせ • Mar 30Sight Sciences Inc Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages Against Alcon IncSight Sciences, Inc. had announced that the U.S. District Court for the District of Delaware issued an order on post-trial motions in Sight Sciences’ patent infringement case against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, Alcon) originally filed on September 16, 2021, that preserved the jury’s verdict of willful infringement. Sight Sciences asserted that Alcon’s sale of the Hydrus Microstent infringed three Sight Sciences patents. The Court’s order was entered on March 27, 2026. The order did not disturb the jury’s verdict that Alcon willfully infringed all three of Sight Sciences’ asserted patents and awarded monetary damages of $34 million, plus supplemental damages and interest, for past infringement, plus an ongoing royalty of 10% of Hydrus revenue through November 10, 2028, the date of expiration of Sight Sciences’ last asserted patent. A final judgment is expected to be entered by the Court in the coming months after supplemental damages and pre-judgment interest have been calculated. The Court’s final judgment is subject to appeal by Alcon. The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The past monetary damages are comprised of $5.5 million in lost profits and $28.5 million in royalty damages for Hydrus sales for the period commencing from its commercial launch through the jury verdict, plus pre-judgment and post-judgment interest and supplemental damages for Hydrus sales during the period between the jury’s verdict and the Court’s entry of the final judgment, in amounts to be determined after Alcon produces supplemental financial data. The final judgment, if upheld, would entitle Sight Sciences to ongoing royalties at a rate of 10% of revenue for each Hydrus sold for the period after entry of the final judgment through the expiration of the last asserted patent, which is set to expire on November 10, 2028. The final judgment is subject to appeal, and may be affected by ex parte reexamination proceedings filed by Alcon in front of the U.S. Patent and Trademark Office.Reported Earnings • Feb 25Full year 2025 earnings released: EPS: US$1.99 (vs US$2.06 in FY 2024)Full year 2025 results: EPS: US$1.99 (down from US$2.06 in FY 2024). Revenue: US$10.4b (up 4.9% from FY 2024). Net income: US$980.0m (down 3.7% from FY 2024). Profit margin: 9.4% (in line with FY 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Italy.お知らせ • Feb 25+ 2 more updatesAlcon Inc., Annual General Meeting, Apr 30, 2026Alcon Inc., Annual General Meeting, Apr 30, 2026.お知らせ • Feb 17Alcon Launches Total30 Multifocal for Astigmatism, the Monthly Multifocal Toric Contact Lens with Water Gradient TechnologyAlcon announced the U.S. launch of TOTAL30®? Multifocal for Astigmatism, the world's only multifocal toric contact lens with Water Gradient Technology, helping patients stay in lenses comfortably,+ as their vision changes from standard correction to age-related presbyopia. These lenses provide excellent end-of-day comfort with wearers rating nearly 8/10, even on day 30, providing patients clear, seamless and stable vision at all distances, near through far. The lenses are now available across the U.S., enabling Eye Care Professionals (ECPs) to offer them to patients nationwide. As the contact lens patient population ages, the need for multifocal toric contact lenses continues to grow. However, the current multifocal toric segment remains underdeveloped, offering ECPs limited contact lens options to recommend. Presently, contact lens drop-out rate is four times higher in presbyopes versus wearers below age 40 due to comfort.4-6 Ast paradigm presbyopic patients also have fewer choices to stay in contact lenses. These factors contribute to the lower adoption rate of multifocal toric contact lenses -- just 7% of ast spherical presbyopes are prescribed contact lenses only. Total30 Multifocal for Ast Astigmatism contact lenses combine unique lens material and leading optical designs to provide astigmatopes with unmatched benefits at a comfortable price, including: Water Gradient Material: Featuring nearly 100% water at the surface,+ so nothing touches the eye but a gentle corrosion of moisture. PRECISION PROFILE®?: The leading optical design for presbyopia correction in the world. PRECISION BALANCE 8|4®?: Delivering the on-eye stability astigmats need for consistent, stable vision. CELLIGENT™? Technology: The biomimetic contact lens surface that helps resist bacteria and lipid deposits, providing patients with an inherently+ clean lens.11-14+ UV Blocking and Blue-Violet Light Filtering: TOTAL30 is the only monthly replacement contact lens family providing Ultraviolet blocking# and Blue-Violet Light filtration. In clinical assessments, patients wearing TOTAL30Multifocal for Astigmatism reported clear 20/20 vision, offering seamless vision at all distances for early, moderate and advanced presbyopia.1 Most notably, ECPs also rated ease of fit 9/10 and the broad range of diopters accommodates nearly 90% of astigmatopes.10,15 Additionally, the PRECISION PROFILE and PRECISION BALANCE 8 |4 innovations made meaningful contributions to the reported 97% success rate for first-lens fit.Board Change • Feb 13Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 03Alcon Debuts PRECISION7 in Canada, A One-Week Replacement Contact Lens to Start and End Every Week FreshAlcon announced the Canadian launch of PRECISION7 sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO System that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 The lenses will be commercially available in Canada in February. While nearly nine out of ten Eye Care Professionals (ECPs) believe daily disposable lenses are better overall for their patients, more than half of new patients are still being fit in reusable lenses due to cost consideration. Most optometrists agree that a one-week contact lens replacement schedule would be more intuitive for patients, as compared to a two-week replacement schedule. PRECISION7 offers a breakthrough in comfort performance and an easy to remember replacement schedule when daily disposables are not an option. The innovation of the ACTIV-FLO System in PRECISION7 is a unique combination of a water-loving moisturizing agent embedded in the lens matrix and a proprietary replenishing agent that is continually released to moisturize the surface for 7 days. With PRECISION7, patients can pick their preferred day of the week to replace their contact lenses to start and end every week fresh. The launch of PRECISION7 marks the newest addition to the Alcon Water Innovations portfolio of contact lenses. PRECISION7 sphere and toric will be available in Canada beginning February 2, 2026. See product instructions for complete wear, care, and safety information.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: US$0.48 (vs US$0.53 in 3Q 2024)Third quarter 2025 results: EPS: US$0.48 (down from US$0.53 in 3Q 2024). Revenue: US$2.61b (up 6.5% from 3Q 2024). Net income: US$237.0m (down 9.9% from 3Q 2024). Profit margin: 9.1% (down from 11% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Italy.お知らせ • Nov 12+ 1 more updateAlcon Inc. Announces Impairments of Property, Plant & Equipment and Intangible Assets for Ended September 30, 2025Alcon Inc. announced Impairments of property, plant & equipment and intangible assets for ended September 30, 2025. For the quarter, the company announced the Impairments of property, plant & equipment and intangible assets of $2 million.お知らせ • Sep 16Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency for Cataract and Vitreoretinal Surgery with UNITY VCSAlcon announced results from time and motion studies demonstrating superior efficiency with UNITY®? Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery compared to CONSTELLATION®? Vision Systemand CENTURION®? Vision System with ACTIVE SENTRY®?. The studies were presented during the 25thEuretina Congress (Paris; 4-7 September), The Retina Society's 58th Annual Scientific Meeting (Chicago; 10-13 September) and the 43rdCongress of the European Society of Cataract and Refractive Surgeons (ESCRS; Copenhagen; 12-15 September). Vitreoretinal and catar act ORs are facing multiple challenges. Globally, the number of age-related macular degeneration (AMD) and diabetic retinopathy patients will increase 46.9% and 55% by 2040 and 2045, respectively. Additionally, between 1990 and 2021, the global prevalence of cataracts increased by nearly 138% from 42.3 million to 100.5 million.8 These patient populations are also contending with a 12% decline in othalmologists worldwide, leaving fewer Eye Care Professionals to keep up with the growing demand.9 Surgical technologies that can help fill these gaps by supporting workflow efficiencies are critical, and Alcon's latest clinical studies demonstrate commitment to generating these solutions. The first study--a prospective, observational, controlled, multi-site time and motion study (total n=179 surgical cases--used objective, videography-based measurements to directly compare UNITY VCS (n=92) against the CONSTELLATION Vision System (n=87) in vitreoretinal surgery. Investigators assessed the duration of console set-up, intraoperative time and tear-down time of 25-gauge (Ga) vitrectomy surgeries. Study results demonstrated UNITY VCS provides a 16% efficiency gain in overall workflow. UNITY VCS provides statistically significant efficiencies in console set-up (33%) and tear-down (38%). The second study presented--an observational, pre-post, multi-site time and Motion analysis evaluated console setup and full procedure turnover for cataract surgeries (total n=303 patients) using UNITY VCS with either the Intelligent Sentry handpiece or the ACTIVE SENTRY handpiece (n=142), compared to the CENTURIONVision System with ACTIVE SENTry handpiece (n=161). The results of the study demonstrate that UNITY VCS reduces cataract surgery turnover time by 6%. In addition, reductions in total energy into the eye (35%) and ultrasound time (8%), were observed.Board Change • Sep 10Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 08Alcon Launches Innovations and Highlights New Study Findings At ESCRS 2025Alcon will present compelling scientific data at the 43rdCongress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen, Denmark from 12-15 September. During the meeting, Alcon will showcase groundbreaking cataract, refractive and glaucoma technologies at booth C2.033. More than 40 studies will also be presented at the meeting, demonstrating the benefits of Alcon technologies. In addition, Alcon will host a number of symposia and activities, which are detailed at MyAlcon.com. Voyager DSLT simplifies selective laser trabeculoplasty (SLT) by streamlining practice workflows and is designed to deliver an exceptional experience for patients, helping accelerate the adoption of laser as a first-line therapy.18-22 Intelligent Service Solutions (ISS)--launches globally, transforming Alcon Services, designed to maximize customer productivity by enabling remote diagnostics and software updates. The new ISS customer portal provides a comprehensive dashboard view of Alcon devices--housing warranty information, contract details and a device connectivity overview. New results being presented at ESCRS add to its robust body of evidence of more than 10 clinical studies in 700+ patients demonstrating positive outcomes and/or patient satisfaction following Vivity IOL implantations in special populations, including: Dr. Antonio Cartabellotta will present spectacle independence and dys photopsia data in cataract patients with early-to-intermediate dry AMD. e-Poster On demand. Dr. Erika Bonacci will present findings from bilateral implantation in cataract patients with mild corneal irregularities such as keratoconus. Dr. Daniel Schartmuller will showcase results of EDOF IOL implantation in patients with mild irregular astigmatism. New data will be presented on UNITY VCS as well as studies highlighting the benefits of operating at more physiologic IOP, including reduced breakthrough pain medication use. Dr. Vance Thompson will present early single-arm data from UNITY VCS demonstrating accurate IOP control, with validation and verification supported by video analysis. e-Poster Ondemand. Dr. Hisaharu Suzuki will showcase anterior chamber stability during cataract surgery using UNITY VCS compared to CENTURION with Active Sentry. Dr. Matthew Rauen will showcase data on patient comfort and intraoperative medications when operating at more physiologic Iop during cataract surgery with CENTURION with Active SentRY. In refractive, Alcon will present wavelight plus head-to-head data, revealing better outcomes versus more commonly used technologies: Dr. John Kanellopoulos will highlight results supporting superior visual outcomes with ray-tracing-guided LASIK using Alcon's wavelight plus, compared to lenticule extraction (SMILE Pro, Zeiss) for myopia correction.お知らせ • Sep 04Alcon Inc. (SWX:ALC) acquired LumiThera, Inc.Alcon Inc. (SWX:ALC) announced its intention to acquire LumiThera, Inc. on July 7, 2025. The transaction includes LumiThera's Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration, but does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun-off to LumiThera’s shareholders prior to Alcon’s acquisition. The transaction is subject to customary closing conditions and approval of offer by LumiThera's shareholders. The expected completion of the transaction is in the third quarter of 2025. Faiz Ahmad, A. Caroline M.Frizzo, Moshe Spinowitz, Resa Schlossberg, Timothy Nelson, Ryne Posey, Maya Florence of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Alcon Inc. (SWX:ALC). Alcon Inc. (SWX:ALC) completed the acquisition of LumiThera, Inc. on September 3, 2025.Reported Earnings • Aug 20Second quarter 2025 earnings released: EPS: US$0.35 (vs US$0.45 in 2Q 2024)Second quarter 2025 results: EPS: US$0.35 (down from US$0.45 in 2Q 2024). Revenue: US$2.60b (up 4.0% from 2Q 2024). Net income: US$176.0m (down 21% from 2Q 2024). Profit margin: 6.8% (down from 8.9% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Italy.お知らせ • Aug 20+ 1 more updateAlcon Inc. Updates Earnings Guidance for the Year 2025Alcon Inc. updated earnings guidance for the year 2025. For the year, the company expects net sales to be $10.3 billion to $10.4 billion against previous forecast of $10.4 billion to $10.5 billion and Core diluted EPS to be $3.05 to $3.15 against previous forecast of $3.05 to $3.15.お知らせ • Aug 19Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment At APACRSAlcon announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone at booth #A1). These comprehensive activities combined with new data underscore Alcon's commitment to generating meaningful scientific evidence on the safety and efficacy of its innovations. Key data being presented at this year's event: Alcon's Vivity®? is an extensively studied Extended Depth of Focus (EDOF) intraocular lens (IOL) in special populations with different co-morbidities, supported by over 10 clinical studies involving more than 700 patients. Among these is a prospective study titled, 'To Evaluate The Visual Outcomes and Patient satisfaction After Bilateral Vivity®? IOL Implantation in Patients with Mild Ir regular Astigmatism.' Conducted by Dr. Ashvin Agarwal, analyses reinforce patient satisfaction outcomes with Vivity in this specific cohort. (Friday, 22 August 2025, 15:20pm-15:25pm, at FFP3-15, Seminar Hall 2, MMCEC).Board Change • Aug 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Independent Chairman Mike Ball was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 05+ 1 more updateAlcon Inc. to Report Q2, 2025 Results on Aug 06, 2025Alcon Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Rocky Bono was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 08Alcon's Latest Breakthrough Surgical Technology, Unity VCS, Receives Health Canada ApprovalAlcon announced that UNITY®? Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. Unity VCS is Alcon's most advanced vitreoretinal and cataract surgical innovations combined together in one integrated platform. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon's current systems, CONSTELLATION®? Vision System for vitreoretinal and combined procedures, and CENTURION®? Vision System with ACTIVE SENTRY®? for cataract surgery. Unity VCS leverages a novel phacoemulsification modality to deliver up to two times faster nucleus removal with 40% less energy into the eye, and a first-of-its-kind phaco handpiece that estimates temperature at the incision site3. In vitreoretinal advancements, the new technology offers cutting speeds of up to 30,000 cuts per minute, the world's fastest vitrectomy probe#,2,3. The platform offers surgical stability and efficiency with a unique proprietary fluidics system. Alcon has tested Unity VCS during investigational advisory wet lab sessions with more than 200 highly experienced surgeons from 30+ countries. Commercial launch of Unity VCS is expected in early 2026. Unity VCS is the latest innovation from the Alcon Vision Suite--a portfolio of innovative products designed to help Eye Care Professionals increase clinic and OR efficiency, and deliver exceptional patient experiences. The Alcon Vision Suite will continue to grow with cutting-edge Unity products that are expected to be introduced over the coming years, adding to market-leading legacy products, which will continue to be available and serviceable. Unity VCS will be supported by Alcon's training, product maintenance, and Services teams.お知らせ • Jul 07Alcon Inc. (SWX:ALC) announced its intention to acquire LumiThera, Inc.Alcon Inc. (SWX:ALC) announced its intention to acquire LumiThera, Inc. on July 7, 2025. The transaction includes LumiThera's Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration, but does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun-off to LumiThera’s shareholders prior to Alcon’s acquisition. The transaction is subject to customary closing conditions and approval of offer by LumiThera's shareholders. The expected completion of the transaction is in the third quarter of 2025. Faiz Ahmad, A. Caroline M.Frizzo, Moshe Spinowitz, Resa Schlossberg, Timothy Nelson, Ryne Posey, Maya Florence of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Alcon Inc. (SWX:ALC).お知らせ • Jun 20Alcon Introduces Clareon PanOptix Pro in Canada, Delivering Low Light Scatter of Any Trifocal IOLAlcon announced the approval of Clareon®? PanOptix®? Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN®? NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,+, PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.1-4,4, These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,++,++ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.10-13,SS,SSSS,SSSS,SS SS,SSSS,SSSS. PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe®? preloaded delivery system and as well as with the Clareon Monarch®? IV delivery system in early 2026.22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be availability with blue light and ultraviolet filtering.22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix ProTrifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the directions for Use regarding indications, precautions, precautions and warnings which is available at ifu.alcon.com.お知らせ • May 29Alcon Announces FDA Approval of TRYPTYR (acoltremon Ophthalmic Solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye DiseaseAlcon announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR®? (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED). TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production. DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation.5-7 Many commonly used DED treatment options have limitations, including slow onset, patient dissatisfaction and poor adherence.8-14 Among surveyed dry eye patients, only 13% felt their dry eye was well managed. This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients (randomized 1:1 to TRYPTYR or vehicle) with a history of DED.1-2 In COMET-2 and COMET-3, up to four times more TRYPTYR patients experienced at least a 10mm increase in natural tear production at Day 14, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p TRYPTYR (acoltremon o eye solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Lenses may be reinserted 15 minutes following administration of TRYPTYR. In clinical trials, the most common adverse reaction was instillation site pain (50%).Reported Earnings • May 14First quarter 2025 earnings released: EPS: US$0.71 (vs US$0.50 in 1Q 2024)First quarter 2025 results: EPS: US$0.71 (up from US$0.50 in 1Q 2024). Revenue: US$2.47b (flat on 1Q 2024). Net income: US$350.0m (up 41% from 1Q 2024). Profit margin: 14% (up from 10% in 1Q 2024). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.お知らせ • May 14Alcon Inc. Revises Earnings Guidance for the Year 2025Alcon Inc. revised earnings guidance for the year 2025. For the year, the company expects net sales to be $10.4 billion to $10.5 billion against previous forecast of $10.2 billion to $10.4 billion; Core diluted EPS to be $3.00 to $3.15 against previous forecast of $3.15 to $3.25.Board Change • May 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Rocky Bono was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 07+ 1 more updateAlcon Inc. Elects Deborah Di Sanzo to the Board, Effective as of September 1, 2025Alcon Inc. announced the approval of all proposed resolutions at its 2025 Annual General Meeting. Shareholders also elected Deborah Di Sanzo to the Board, effective as of September 1, 2025.株主還元1ALCIT Medical EquipmentIT 市場7D0.8%-2.1%0.8%1Y-21.7%-15.6%29.1%株主還元を見る業界別リターン: 1ALC過去 1 年間で-15.6 % の収益を上げたItalian Medical Equipment業界を下回りました。リターン対市場: 1ALCは、過去 1 年間で29.1 % のリターンを上げたItalian市場を下回りました。価格変動Is 1ALC's price volatile compared to industry and market?1ALC volatility1ALC Average Weekly Movement4.7%Medical Equipment Industry Average Movement4.5%Market Average Movement4.8%10% most volatile stocks in IT Market8.3%10% least volatile stocks in IT Market2.9%安定した株価: 1ALC 、 Italian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 1ALCの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト194525,000David Endicottwww.alcon.comアルコン社はアイケア製品の研究、開発、製造、流通、販売を世界中で行っている。サージカル事業とビジョンケア事業の2部門を展開。同社は、機器、器具、診断、眼内レンズ（IOL）、その他のインプラント製品、および粘弾性体、手術用溶液、切開器具、手術用カスタムパック、その他の手術用製品を含む消耗品を提供している。白内障製品としては、Centurionビジョンシステム、LenSxレーザーシステム、VerionリファレンスユニットおよびVerionデジタルマーカー、ARGOSバイオメーター、SMARTCATARACTヘルスプラットフォーム、NGENUITY3D可視化システム、LuxOR手術用眼科顕微鏡、術中測定用ORAシステム、移植製品としては、単焦点眼内レンズ、トーリック眼内レンズ、老視矯正眼内レンズ、AutonoMeやUltraSertなどのデリバリーシステムなどがある。さらに、コンステレーションビジョンシステム、プロシージャパック、レーザー、ハンドヘルドマイクロサージェリー器具、グリースハーバー、MIVS器具、はさみ、鉗子、マイクロ器具、医療グレードの硝子体タンポナーデ、ハイパービット硝子体手術プローブで構成されるカスタムパック手術用プロシージャパック網膜硝子体製品、レーシック屈折矯正手術に使用されるウェーブライトやコントゥーラビジョンなどの屈折矯正手術用製品を提供している。さらに、1日使い捨てコンタクトレンズ、再使用可能コンタクトレンズ、カラー強化コンタクトレンズ、ドライアイ、眼アレルギー、緑内障、コンタクトレンズケアなどの眼科用健康製品、眼用ビタミン剤、充血緩和剤なども提供している。以前はアルコン・ユニバーサルS A.として知られていたが、2001年12月にアルコン・インクに社名を変更した。アルコン社は1945年に設立され、スイスのジュネーブに本社を置いている。もっと見るAlcon Inc. 基礎のまとめAlcon の収益と売上を時価総額と比較するとどうか。1ALC 基礎統計学時価総額€27.88b収益（TTM）€718.67m売上高(TTM)€9.33b39.2xPER（株価収益率3.0xP/Sレシオ1ALC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1ALC 損益計算書（TTM）収益US$10.63b売上原価US$4.66b売上総利益US$5.97bその他の費用US$5.15b収益US$819.00m直近の収益報告Mar 31, 2026次回決算日Aug 11, 2026一株当たり利益（EPS）1.68グロス・マージン56.14%純利益率7.70%有利子負債／自己資本比率21.4%1ALC の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.5%現在の配当利回り21%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 22:11終値2026/06/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alcon Inc. 23 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。58 アナリスト機関null nullArgus Research Companynull nullBairdJeffrey JohnsonBaird55 その他のアナリストを表示
Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €53.20, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Medical Equipment industry in Italy. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €84.18 per share.
お知らせ • May 08+ 1 more updateAlcon Inc. (SWX:ALC) announces an Equity Buyback for $1,500 million worth of its shares.Alcon Inc. (SWX:ALC) announces a share repurchase program. Under the program, the company will repurchase up to $1,500 million worth of its shares. The shares to be acquired under this share buyback program will be cancelled as a return of capital to shareholders. The repurchases will be funded through cash generated from operations. The repurchase program will be valid for 3 years.
New Risk • May 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.7% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
お知らせ • May 02Alcon Inc. Elects R. Scott Herren as New Independent Member of the BoardAlcon Inc. at its Annual General Meeting of 2026 elected R. Scott Herren as new independent member of the Board.
Upcoming Dividend • Apr 28Upcoming dividend of CHF0.28 per shareEligible shareholders must have bought the stock before 05 May 2026. Payment date: 07 May 2026. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.6%). Lower than average of industry peers (2.3%).
Board Change • Apr 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €53.20, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Medical Equipment industry in Italy. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €84.18 per share.
お知らせ • May 08+ 1 more updateAlcon Inc. (SWX:ALC) announces an Equity Buyback for $1,500 million worth of its shares.Alcon Inc. (SWX:ALC) announces a share repurchase program. Under the program, the company will repurchase up to $1,500 million worth of its shares. The shares to be acquired under this share buyback program will be cancelled as a return of capital to shareholders. The repurchases will be funded through cash generated from operations. The repurchase program will be valid for 3 years.
New Risk • May 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.7% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
お知らせ • May 02Alcon Inc. Elects R. Scott Herren as New Independent Member of the BoardAlcon Inc. at its Annual General Meeting of 2026 elected R. Scott Herren as new independent member of the Board.
Upcoming Dividend • Apr 28Upcoming dividend of CHF0.28 per shareEligible shareholders must have bought the stock before 05 May 2026. Payment date: 07 May 2026. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.6%). Lower than average of industry peers (2.3%).
Board Change • Apr 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 07Alcon Inc Launches Clareon Truplus Enhanced Design Monofocal And Toric IOLsAlcon Inc. announced the U.S. launch of Clareon TruPlus, its new enhanced design monofocal and toric intraocular lens (IOL), at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. TruPlus expands Alcon’s Clareon portfolio, offering surgeons an enhanced design IOL, enabling increased depth of focus without compromising the high-quality distance vision they expect from a monofocal IOL. Based on bench data, TruPlus has a number of differentiating features over Clareon Monofocal and the leading competitor IOL. TruPlus demonstrates a 3.5 letter improvement in simulated visual acuity at -1.5 diopters (66 cm) compared to Clareon Monofocal. TruPlus offers higher distance image quality than TECNIS Eyhance across a range of pupil sizes and lighting conditions. TruPlus exceeds the ISO upper requirement for distance image quality. TruPlus demonstrates a lower glare and halo profile than TECNIS Eyhance. TruPlus leverages proprietary Opti-Balance Technology in the center of the lens to slightly extend the depth of focus. This innovative design boosts light energy for an increased depth of focus, while maintaining exceptional distance image quality and a wide refractive landing zone. With more than 175 million IOLs implanted globally, TruPlus joins Alcon’s portfolio of Clareon IOLs that includes the number one monofocal; Vivity, the extended depth of focus IOL; PanOptix Pro and PanOptix, the trifocal IOL. TruPlus will launch in additional markets later this year. At ASCRS, Alcon will also feature more than 60 scientific presentations and peer-to-peer educational symposia. Studies presented include First Clinical Experience with a Novel Phacoemulsification System, Anterior Chamber Stability of a Novel Phacoemulsification System Assessed by Intraoperative OCT and Surgical Microscope Video, Prospective Intraindividual Comparison of Functional Outcomes After Automated Customized Ray Tracing Guided vs. Wavefront Optimized LASIK, Perioperative Benefits of a Personalized LASIK Approach Using 3D Ray Tracing Technology: A Modified Delphi Study, High Tear Production Responder Rates Associated with the Novel TRPM8 Agonist Acoltremon: Phase 3 COMET2 and COMET3 Results, Tear Volume and Total Lipid Concentration Following Administration of Acoltremon 0.003%, Optical Bench Comparison of Two Enhanced Monofocal IOLs, and Direct Comparison of the Visual Disturbances Induced by Two Enhanced Monofocal IOLs. The Clareon Family of Lenses are artificial lenses implanted in the eye of adult patients following cataract surgery. The Clareon TruPlus IOLs are designed to allow for clear distance vision. The Clareon TruPlus Toric IOLs are designed to correct pre-existing corneal astigmatism, which is the inability of the eye to focus clearly at any distance because of different curvatures on the cornea, and provide distance vision. These IOLs are intended for placement in the capsular bag. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon, informing them of possible risks and benefits associated with these IOLs. Reference the Directions for Use labelling for each IOL for a complete listing of indications, warnings and precautions.
Declared Dividend • Apr 05Dividend of CHF0.28 announcedShareholders will receive a dividend of CHF0.28. Ex-date: 5th May 2026 Payment date: 7th May 2026 Dividend yield will be 0.4%, which is lower than the industry average of 1.7%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 11%.
お知らせ • Apr 03Alcon Inc. announces Annual dividend, payable on May 07, 2026Alcon Inc. announced Annual dividend of CHF 0.2800 per share payable on May 07, 2026, ex-date on May 05, 2026 and record date on May 06, 2026.
お知らせ • Mar 30Sight Sciences Inc Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages Against Alcon IncSight Sciences, Inc. had announced that the U.S. District Court for the District of Delaware issued an order on post-trial motions in Sight Sciences’ patent infringement case against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, Alcon) originally filed on September 16, 2021, that preserved the jury’s verdict of willful infringement. Sight Sciences asserted that Alcon’s sale of the Hydrus Microstent infringed three Sight Sciences patents. The Court’s order was entered on March 27, 2026. The order did not disturb the jury’s verdict that Alcon willfully infringed all three of Sight Sciences’ asserted patents and awarded monetary damages of $34 million, plus supplemental damages and interest, for past infringement, plus an ongoing royalty of 10% of Hydrus revenue through November 10, 2028, the date of expiration of Sight Sciences’ last asserted patent. A final judgment is expected to be entered by the Court in the coming months after supplemental damages and pre-judgment interest have been calculated. The Court’s final judgment is subject to appeal by Alcon. The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The past monetary damages are comprised of $5.5 million in lost profits and $28.5 million in royalty damages for Hydrus sales for the period commencing from its commercial launch through the jury verdict, plus pre-judgment and post-judgment interest and supplemental damages for Hydrus sales during the period between the jury’s verdict and the Court’s entry of the final judgment, in amounts to be determined after Alcon produces supplemental financial data. The final judgment, if upheld, would entitle Sight Sciences to ongoing royalties at a rate of 10% of revenue for each Hydrus sold for the period after entry of the final judgment through the expiration of the last asserted patent, which is set to expire on November 10, 2028. The final judgment is subject to appeal, and may be affected by ex parte reexamination proceedings filed by Alcon in front of the U.S. Patent and Trademark Office.
Reported Earnings • Feb 25Full year 2025 earnings released: EPS: US$1.99 (vs US$2.06 in FY 2024)Full year 2025 results: EPS: US$1.99 (down from US$2.06 in FY 2024). Revenue: US$10.4b (up 4.9% from FY 2024). Net income: US$980.0m (down 3.7% from FY 2024). Profit margin: 9.4% (in line with FY 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Italy.
お知らせ • Feb 25+ 2 more updatesAlcon Inc., Annual General Meeting, Apr 30, 2026Alcon Inc., Annual General Meeting, Apr 30, 2026.
お知らせ • Feb 17Alcon Launches Total30 Multifocal for Astigmatism, the Monthly Multifocal Toric Contact Lens with Water Gradient TechnologyAlcon announced the U.S. launch of TOTAL30®? Multifocal for Astigmatism, the world's only multifocal toric contact lens with Water Gradient Technology, helping patients stay in lenses comfortably,+ as their vision changes from standard correction to age-related presbyopia. These lenses provide excellent end-of-day comfort with wearers rating nearly 8/10, even on day 30, providing patients clear, seamless and stable vision at all distances, near through far. The lenses are now available across the U.S., enabling Eye Care Professionals (ECPs) to offer them to patients nationwide. As the contact lens patient population ages, the need for multifocal toric contact lenses continues to grow. However, the current multifocal toric segment remains underdeveloped, offering ECPs limited contact lens options to recommend. Presently, contact lens drop-out rate is four times higher in presbyopes versus wearers below age 40 due to comfort.4-6 Ast paradigm presbyopic patients also have fewer choices to stay in contact lenses. These factors contribute to the lower adoption rate of multifocal toric contact lenses -- just 7% of ast spherical presbyopes are prescribed contact lenses only. Total30 Multifocal for Ast Astigmatism contact lenses combine unique lens material and leading optical designs to provide astigmatopes with unmatched benefits at a comfortable price, including: Water Gradient Material: Featuring nearly 100% water at the surface,+ so nothing touches the eye but a gentle corrosion of moisture. PRECISION PROFILE®?: The leading optical design for presbyopia correction in the world. PRECISION BALANCE 8|4®?: Delivering the on-eye stability astigmats need for consistent, stable vision. CELLIGENT™? Technology: The biomimetic contact lens surface that helps resist bacteria and lipid deposits, providing patients with an inherently+ clean lens.11-14+ UV Blocking and Blue-Violet Light Filtering: TOTAL30 is the only monthly replacement contact lens family providing Ultraviolet blocking# and Blue-Violet Light filtration. In clinical assessments, patients wearing TOTAL30Multifocal for Astigmatism reported clear 20/20 vision, offering seamless vision at all distances for early, moderate and advanced presbyopia.1 Most notably, ECPs also rated ease of fit 9/10 and the broad range of diopters accommodates nearly 90% of astigmatopes.10,15 Additionally, the PRECISION PROFILE and PRECISION BALANCE 8 |4 innovations made meaningful contributions to the reported 97% success rate for first-lens fit.
Board Change • Feb 13Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 03Alcon Debuts PRECISION7 in Canada, A One-Week Replacement Contact Lens to Start and End Every Week FreshAlcon announced the Canadian launch of PRECISION7 sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO System that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 The lenses will be commercially available in Canada in February. While nearly nine out of ten Eye Care Professionals (ECPs) believe daily disposable lenses are better overall for their patients, more than half of new patients are still being fit in reusable lenses due to cost consideration. Most optometrists agree that a one-week contact lens replacement schedule would be more intuitive for patients, as compared to a two-week replacement schedule. PRECISION7 offers a breakthrough in comfort performance and an easy to remember replacement schedule when daily disposables are not an option. The innovation of the ACTIV-FLO System in PRECISION7 is a unique combination of a water-loving moisturizing agent embedded in the lens matrix and a proprietary replenishing agent that is continually released to moisturize the surface for 7 days. With PRECISION7, patients can pick their preferred day of the week to replace their contact lenses to start and end every week fresh. The launch of PRECISION7 marks the newest addition to the Alcon Water Innovations portfolio of contact lenses. PRECISION7 sphere and toric will be available in Canada beginning February 2, 2026. See product instructions for complete wear, care, and safety information.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: US$0.48 (vs US$0.53 in 3Q 2024)Third quarter 2025 results: EPS: US$0.48 (down from US$0.53 in 3Q 2024). Revenue: US$2.61b (up 6.5% from 3Q 2024). Net income: US$237.0m (down 9.9% from 3Q 2024). Profit margin: 9.1% (down from 11% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Italy.
お知らせ • Nov 12+ 1 more updateAlcon Inc. Announces Impairments of Property, Plant & Equipment and Intangible Assets for Ended September 30, 2025Alcon Inc. announced Impairments of property, plant & equipment and intangible assets for ended September 30, 2025. For the quarter, the company announced the Impairments of property, plant & equipment and intangible assets of $2 million.
お知らせ • Sep 16Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency for Cataract and Vitreoretinal Surgery with UNITY VCSAlcon announced results from time and motion studies demonstrating superior efficiency with UNITY®? Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery compared to CONSTELLATION®? Vision Systemand CENTURION®? Vision System with ACTIVE SENTRY®?. The studies were presented during the 25thEuretina Congress (Paris; 4-7 September), The Retina Society's 58th Annual Scientific Meeting (Chicago; 10-13 September) and the 43rdCongress of the European Society of Cataract and Refractive Surgeons (ESCRS; Copenhagen; 12-15 September). Vitreoretinal and catar act ORs are facing multiple challenges. Globally, the number of age-related macular degeneration (AMD) and diabetic retinopathy patients will increase 46.9% and 55% by 2040 and 2045, respectively. Additionally, between 1990 and 2021, the global prevalence of cataracts increased by nearly 138% from 42.3 million to 100.5 million.8 These patient populations are also contending with a 12% decline in othalmologists worldwide, leaving fewer Eye Care Professionals to keep up with the growing demand.9 Surgical technologies that can help fill these gaps by supporting workflow efficiencies are critical, and Alcon's latest clinical studies demonstrate commitment to generating these solutions. The first study--a prospective, observational, controlled, multi-site time and motion study (total n=179 surgical cases--used objective, videography-based measurements to directly compare UNITY VCS (n=92) against the CONSTELLATION Vision System (n=87) in vitreoretinal surgery. Investigators assessed the duration of console set-up, intraoperative time and tear-down time of 25-gauge (Ga) vitrectomy surgeries. Study results demonstrated UNITY VCS provides a 16% efficiency gain in overall workflow. UNITY VCS provides statistically significant efficiencies in console set-up (33%) and tear-down (38%). The second study presented--an observational, pre-post, multi-site time and Motion analysis evaluated console setup and full procedure turnover for cataract surgeries (total n=303 patients) using UNITY VCS with either the Intelligent Sentry handpiece or the ACTIVE SENTRY handpiece (n=142), compared to the CENTURIONVision System with ACTIVE SENTry handpiece (n=161). The results of the study demonstrate that UNITY VCS reduces cataract surgery turnover time by 6%. In addition, reductions in total energy into the eye (35%) and ultrasound time (8%), were observed.
Board Change • Sep 10Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Independent Director Deborah DiSanzo Eldracher was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 08Alcon Launches Innovations and Highlights New Study Findings At ESCRS 2025Alcon will present compelling scientific data at the 43rdCongress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen, Denmark from 12-15 September. During the meeting, Alcon will showcase groundbreaking cataract, refractive and glaucoma technologies at booth C2.033. More than 40 studies will also be presented at the meeting, demonstrating the benefits of Alcon technologies. In addition, Alcon will host a number of symposia and activities, which are detailed at MyAlcon.com. Voyager DSLT simplifies selective laser trabeculoplasty (SLT) by streamlining practice workflows and is designed to deliver an exceptional experience for patients, helping accelerate the adoption of laser as a first-line therapy.18-22 Intelligent Service Solutions (ISS)--launches globally, transforming Alcon Services, designed to maximize customer productivity by enabling remote diagnostics and software updates. The new ISS customer portal provides a comprehensive dashboard view of Alcon devices--housing warranty information, contract details and a device connectivity overview. New results being presented at ESCRS add to its robust body of evidence of more than 10 clinical studies in 700+ patients demonstrating positive outcomes and/or patient satisfaction following Vivity IOL implantations in special populations, including: Dr. Antonio Cartabellotta will present spectacle independence and dys photopsia data in cataract patients with early-to-intermediate dry AMD. e-Poster On demand. Dr. Erika Bonacci will present findings from bilateral implantation in cataract patients with mild corneal irregularities such as keratoconus. Dr. Daniel Schartmuller will showcase results of EDOF IOL implantation in patients with mild irregular astigmatism. New data will be presented on UNITY VCS as well as studies highlighting the benefits of operating at more physiologic IOP, including reduced breakthrough pain medication use. Dr. Vance Thompson will present early single-arm data from UNITY VCS demonstrating accurate IOP control, with validation and verification supported by video analysis. e-Poster Ondemand. Dr. Hisaharu Suzuki will showcase anterior chamber stability during cataract surgery using UNITY VCS compared to CENTURION with Active Sentry. Dr. Matthew Rauen will showcase data on patient comfort and intraoperative medications when operating at more physiologic Iop during cataract surgery with CENTURION with Active SentRY. In refractive, Alcon will present wavelight plus head-to-head data, revealing better outcomes versus more commonly used technologies: Dr. John Kanellopoulos will highlight results supporting superior visual outcomes with ray-tracing-guided LASIK using Alcon's wavelight plus, compared to lenticule extraction (SMILE Pro, Zeiss) for myopia correction.
お知らせ • Sep 04Alcon Inc. (SWX:ALC) acquired LumiThera, Inc.Alcon Inc. (SWX:ALC) announced its intention to acquire LumiThera, Inc. on July 7, 2025. The transaction includes LumiThera's Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration, but does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun-off to LumiThera’s shareholders prior to Alcon’s acquisition. The transaction is subject to customary closing conditions and approval of offer by LumiThera's shareholders. The expected completion of the transaction is in the third quarter of 2025. Faiz Ahmad, A. Caroline M.Frizzo, Moshe Spinowitz, Resa Schlossberg, Timothy Nelson, Ryne Posey, Maya Florence of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Alcon Inc. (SWX:ALC). Alcon Inc. (SWX:ALC) completed the acquisition of LumiThera, Inc. on September 3, 2025.
Reported Earnings • Aug 20Second quarter 2025 earnings released: EPS: US$0.35 (vs US$0.45 in 2Q 2024)Second quarter 2025 results: EPS: US$0.35 (down from US$0.45 in 2Q 2024). Revenue: US$2.60b (up 4.0% from 2Q 2024). Net income: US$176.0m (down 21% from 2Q 2024). Profit margin: 6.8% (down from 8.9% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Italy.
お知らせ • Aug 20+ 1 more updateAlcon Inc. Updates Earnings Guidance for the Year 2025Alcon Inc. updated earnings guidance for the year 2025. For the year, the company expects net sales to be $10.3 billion to $10.4 billion against previous forecast of $10.4 billion to $10.5 billion and Core diluted EPS to be $3.05 to $3.15 against previous forecast of $3.05 to $3.15.
お知らせ • Aug 19Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment At APACRSAlcon announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone at booth #A1). These comprehensive activities combined with new data underscore Alcon's commitment to generating meaningful scientific evidence on the safety and efficacy of its innovations. Key data being presented at this year's event: Alcon's Vivity®? is an extensively studied Extended Depth of Focus (EDOF) intraocular lens (IOL) in special populations with different co-morbidities, supported by over 10 clinical studies involving more than 700 patients. Among these is a prospective study titled, 'To Evaluate The Visual Outcomes and Patient satisfaction After Bilateral Vivity®? IOL Implantation in Patients with Mild Ir regular Astigmatism.' Conducted by Dr. Ashvin Agarwal, analyses reinforce patient satisfaction outcomes with Vivity in this specific cohort. (Friday, 22 August 2025, 15:20pm-15:25pm, at FFP3-15, Seminar Hall 2, MMCEC).
Board Change • Aug 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Independent Chairman Mike Ball was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 05+ 1 more updateAlcon Inc. to Report Q2, 2025 Results on Aug 06, 2025Alcon Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025
Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Rocky Bono was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 08Alcon's Latest Breakthrough Surgical Technology, Unity VCS, Receives Health Canada ApprovalAlcon announced that UNITY®? Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. Unity VCS is Alcon's most advanced vitreoretinal and cataract surgical innovations combined together in one integrated platform. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon's current systems, CONSTELLATION®? Vision System for vitreoretinal and combined procedures, and CENTURION®? Vision System with ACTIVE SENTRY®? for cataract surgery. Unity VCS leverages a novel phacoemulsification modality to deliver up to two times faster nucleus removal with 40% less energy into the eye, and a first-of-its-kind phaco handpiece that estimates temperature at the incision site3. In vitreoretinal advancements, the new technology offers cutting speeds of up to 30,000 cuts per minute, the world's fastest vitrectomy probe#,2,3. The platform offers surgical stability and efficiency with a unique proprietary fluidics system. Alcon has tested Unity VCS during investigational advisory wet lab sessions with more than 200 highly experienced surgeons from 30+ countries. Commercial launch of Unity VCS is expected in early 2026. Unity VCS is the latest innovation from the Alcon Vision Suite--a portfolio of innovative products designed to help Eye Care Professionals increase clinic and OR efficiency, and deliver exceptional patient experiences. The Alcon Vision Suite will continue to grow with cutting-edge Unity products that are expected to be introduced over the coming years, adding to market-leading legacy products, which will continue to be available and serviceable. Unity VCS will be supported by Alcon's training, product maintenance, and Services teams.
お知らせ • Jul 07Alcon Inc. (SWX:ALC) announced its intention to acquire LumiThera, Inc.Alcon Inc. (SWX:ALC) announced its intention to acquire LumiThera, Inc. on July 7, 2025. The transaction includes LumiThera's Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration, but does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun-off to LumiThera’s shareholders prior to Alcon’s acquisition. The transaction is subject to customary closing conditions and approval of offer by LumiThera's shareholders. The expected completion of the transaction is in the third quarter of 2025. Faiz Ahmad, A. Caroline M.Frizzo, Moshe Spinowitz, Resa Schlossberg, Timothy Nelson, Ryne Posey, Maya Florence of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Alcon Inc. (SWX:ALC).
お知らせ • Jun 20Alcon Introduces Clareon PanOptix Pro in Canada, Delivering Low Light Scatter of Any Trifocal IOLAlcon announced the approval of Clareon®? PanOptix®? Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN®? NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,+, PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.1-4,4, These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,++,++ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.10-13,SS,SSSS,SSSS,SS SS,SSSS,SSSS. PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe®? preloaded delivery system and as well as with the Clareon Monarch®? IV delivery system in early 2026.22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be availability with blue light and ultraviolet filtering.22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix ProTrifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the directions for Use regarding indications, precautions, precautions and warnings which is available at ifu.alcon.com.
お知らせ • May 29Alcon Announces FDA Approval of TRYPTYR (acoltremon Ophthalmic Solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye DiseaseAlcon announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR®? (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED). TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production. DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation.5-7 Many commonly used DED treatment options have limitations, including slow onset, patient dissatisfaction and poor adherence.8-14 Among surveyed dry eye patients, only 13% felt their dry eye was well managed. This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients (randomized 1:1 to TRYPTYR or vehicle) with a history of DED.1-2 In COMET-2 and COMET-3, up to four times more TRYPTYR patients experienced at least a 10mm increase in natural tear production at Day 14, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p TRYPTYR (acoltremon o eye solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Lenses may be reinserted 15 minutes following administration of TRYPTYR. In clinical trials, the most common adverse reaction was instillation site pain (50%).
Reported Earnings • May 14First quarter 2025 earnings released: EPS: US$0.71 (vs US$0.50 in 1Q 2024)First quarter 2025 results: EPS: US$0.71 (up from US$0.50 in 1Q 2024). Revenue: US$2.47b (flat on 1Q 2024). Net income: US$350.0m (up 41% from 1Q 2024). Profit margin: 14% (up from 10% in 1Q 2024). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.
お知らせ • May 14Alcon Inc. Revises Earnings Guidance for the Year 2025Alcon Inc. revised earnings guidance for the year 2025. For the year, the company expects net sales to be $10.4 billion to $10.5 billion against previous forecast of $10.2 billion to $10.4 billion; Core diluted EPS to be $3.00 to $3.15 against previous forecast of $3.15 to $3.25.
Board Change • May 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Rocky Bono was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 07+ 1 more updateAlcon Inc. Elects Deborah Di Sanzo to the Board, Effective as of September 1, 2025Alcon Inc. announced the approval of all proposed resolutions at its 2025 Annual General Meeting. Shareholders also elected Deborah Di Sanzo to the Board, effective as of September 1, 2025.
